2070-4909

FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology

IRBIS

View prefix report (10.17749)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 153 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Medium impact153 DOIs
2

Attach ORCID iDs across 125 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact125 DOIs
3

Add license metadata to 116 records

License metadata tells indexers and readers how each article may be reused.

Low impact116 DOIs

DOIs for this ISSN

Showing the top 5 of 454 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS… (10.17749/2070-4909.2015.8.1.047-056)
Abstract References ORCID License
117.61 14
2 THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN T… (10.17749/2070-4909.2017.10.1.066-071)
Abstract References ORCID License
100.00 9
3 EVALUATING THE USE OF HOSPITAL BED CAPACITY IN MEDICAL ORGAN… (10.17749/2070-4909.2017.10.4.037-043)
Abstract References ORCID License
90.31 7
4 EPIDEMIOLOGICAL FEATURES OF NON-ALCOHOLIC FATTY LIVER DISEAS… (10.17749/2070-4909.2016.9.2.017-027)
Abstract References ORCID License
84.51 6
5 EARLY HEALTH TECHNOLOGIES ASSESSMENT — NEW APPROACH TO IMPRO… (10.17749/2070-4909.2016.9.3.053-059)
Abstract References ORCID License
77.82 5
6 Methods of clinical assessment from the “Clinical Recommenda… (10.17749/2070-4909.2018.11.1.056-063)
Abstract References ORCID License
77.82 5
7 COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS… (10.17749/2070-4909.2016.9.1.003-014)
Abstract References ORCID License
69.90 4
8 COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INF… (10.17749/2070-4909.2017.10.2.041-043)
Abstract References ORCID License
69.90 4
9 Provision of free medical care in Russia and elsewhere: revi… (10.17749/2070-4909.2017.10.3.059-065)
Abstract References ORCID License
69.90 4
10 Medical care of ambulatory patients and its assessment: a re… (10.17749/2070-4909.2018.11.1.045-049)
Abstract References ORCID License
69.90 4
11 Options to optimize the access to biosimilars: analysis and… (10.17749/2070-4909.2018.11.1.050-055)
Abstract References ORCID License
69.90 4
12 PHARMACO-ECONOMIC ANALYSIS OF COST IN TERMS OF MAINTENANCE O… (10.17749/2070-4909.2016.9.2.049-059)
Abstract References ORCID License
60.21 3
13 COMPARISON OF RECOMMENDED SCREENING PROGRAMS IN THE UNITED S… (10.17749/2070-4909.2016.9.4.046-053)
Abstract References ORCID License
60.21 3
14 RESTRICTIVE LISTS OF DRUGS: REGULATIONS, FUNCTIONS, SOURCES… (10.17749/2070-4909.2017.10.1.046-056)
Abstract References ORCID License
60.21 3
15 PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR TH… (10.17749/2070-4909.2017.10.2.053-061)
Abstract References ORCID License
60.21 3
16 Comparative pharmaco-economic analysis of using enzalutamide… (10.17749/2070-4909.2017.10.3.012-021)
Abstract References ORCID License
60.21 3
17 Review of the current approaches to the assessment of the dr… (10.17749/2070-4909.2017.10.3.066-074)
Abstract References ORCID License
60.21 3
18 THE INTERNATIONAL PRACTICE OF DRUG SUPPLY IN THE OUTPATIENT… (10.17749/2070-4909.2017.10.4.044-052)
Abstract References ORCID License
60.21 3
19 CYP2D6 genotyping in the daily routine of a psychiatric hosp… (10.17749/2070-4909.2018.11.1.019-026)
Abstract References License
58.36 5
20 Modeling microbial drug-resistance: from mathematics to phar… (10.17749/2070-4909.2018.11.1.027-036)
Abstract References License
52.42 4
21 PROSPECTS FOR THE USE OF METHODS OF ECONOMIC EVALUATION AT T… (10.17749/2070-4909.2016.9.1.079-083)
Abstract References ORCID License
47.71 2
22 BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMEN… (10.17749/2070-4909.2016.9.2.028-037)
Abstract References ORCID License
47.71 2
23 HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENT… (10.17749/2070-4909.2016.9.3.020-028)
Abstract References ORCID License
47.71 2
24 METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREAT… (10.17749/2070-4909.2016.9.3.030-037)
Abstract References ORCID License
47.71 2
25 CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS W… (10.17749/2070-4909.2016.9.3.038-047)
Abstract References ORCID License
47.71 2
26 MONITORING OF CONSUMER ATTITUDES TO MEDICINES (10.17749/2070-4909.2016.9.3.049-052)
Abstract References ORCID License
47.71 2
27 EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THY… (10.17749/2070-4909.2017.10.1.003-010)
Abstract References ORCID License
47.71 2
28 PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN… (10.17749/2070-4909.2017.10.1.039-045)
Abstract References ORCID License
47.71 2
29 INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVE… (10.17749/2070-4909.2017.10.4.015-024)
Abstract References ORCID License
47.71 2
30 SOURCES OF BIAS IN SELF-ASSESSED HEALTH (10.17749/2070-4909.2017.10.4.031-036)
Abstract References ORCID License
47.71 2
31 Meta-analysis of clinical trials of osteoarthritis treatment… (10.17749/2070-4909/farmakoekonomika.2020.066)
Abstract
43.31 53
32 Prevalence survey of musculoskeletal and connective tissue d… (10.17749/2070-4909.2019.12.1.5-13)
Abstract ORCID
42.25 6
33 Comorbidity in elderly patients with atrial fibrillation aff… (10.17749/2070-4909.2019.12.3.191-199)
Abstract ORCID
42.25 6
34 Analysis of 19.9 million publications from the PubMed/MEDLIN… (10.17749/2070-4909/farmakoekonomika.2020.021)
Abstract
36.93 29
35 New framework for the development of clinical guidelines in… (10.17749/2070-4909.2019.12.2.125-144)
Abstract
32.53 19
36 Concept of value-based healthcare (10.17749/2070-4909/farmakoekonomika.2020.042)
Abstract
31.97 18
37 Evaluation of the reference value of the incremental paramet… (10.17749/2070-4909/farmakoekonomika.2020.071)
Abstract
31.38 17
38 Concerning the “repression” of ω -3 polyunsaturated fatty ac… (10.17749/2070-4909.2019.12.2.91-114)
Abstract
30.76 16
39 BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY… (10.17749/2070-4909.2015.8.1.039-046)
Abstract References ORCID License
30.10 1
40 PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX… (10.17749/2070-4909.2016.9.1.015-022)
Abstract References ORCID License
30.10 1
41 SYSTEMATIC REVIEW OF PENTAGLOBIN EFFICACY IN PREVENTING MORT… (10.17749/2070-4909.2016.9.1.050-057)
Abstract References ORCID License
30.10 1
42 REVIEW OF HEALTH SYSTEM ORGANIZATION APPROACHES TO ESTIMATIN… (10.17749/2070-4909.2016.9.1.069-078)
Abstract References ORCID License
30.10 1
43 DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PR… (10.17749/2070-4909.2016.9.3.008-018)
Abstract References ORCID License
30.10 1
44 COPAYMENTS OF THE CITIZENS IN HEALTHCARE SYSTEM: INTERNATION… (10.17749/2070-4909.2016.9.3.060-067)
Abstract References ORCID License
30.10 1
45 FACTORS AND EFFECTS OF PRIVATE HEALTH SPENDING (10.17749/2070-4909.2016.9.4.024-030)
Abstract References ORCID License
30.10 1
46 REVIEW OF PRACTICE AND POSSIBLE DIRECTIONS OF CONCRETIZATION… (10.17749/2070-4909.2016.9.4.038-045)
Abstract References ORCID License
30.10 1
47 BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS… (10.17749/2070-4909.2017.10.1.019-028)
Abstract References ORCID License
30.10 1
48 THE PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN OUTPA… (10.17749/2070-4909.2017.10.1.057-065)
Abstract References ORCID License
30.10 1
49 COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF… (10.17749/2070-4909.2017.10.2.012-021)
Abstract References ORCID License
30.10 1
50 COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODAT… (10.17749/2070-4909.2017.10.2.022-030)
Abstract References ORCID License
30.10 1